A real-world data analysis of the use of hepatoprotective drugs in outpatients in six cities of China from 2015 to 2019

ObjectiveTo investigate the use of hepatoprotective drugs in China in recent years, and to put forward related suggestions. MethodsThe outpatient prescription data of hepatoprotective drugs were collected from 85 hospitals in 6 cities of China from 2015 to 2019, and a real-world data analysis was pe...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	ZHAO Zinan
Formato:	article
Lenguaje:	ZH
Publicado:	Editorial Department of Journal of Clinical Hepatology 2021
Materias:	Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/fb411e4816824d9692d1b197993f36d8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fb411e4816824d9692d1b197993f36d8
record_format	dspace
spelling	oai:doaj.org-article:fb411e4816824d9692d1b197993f36d82021-11-17T11:02:36ZA real-world data analysis of the use of hepatoprotective drugs in outpatients in six cities of China from 2015 to 20191001-5256https://doaj.org/article/fb411e4816824d9692d1b197993f36d82021-11-01T00:00:00Zhttp://www.lcgdbzz.org/cn/article/doi/10.3969/j.issn.1001-5256.2021.11.021https://doaj.org/toc/1001-5256ObjectiveTo investigate the use of hepatoprotective drugs in China in recent years, and to put forward related suggestions. MethodsThe outpatient prescription data of hepatoprotective drugs were collected from 85 hospitals in 6 cities of China from 2015 to 2019, and a real-world data analysis was performed to analyze the payment method, issuing department, drug category, and use of hepatoprotective drugs. ResultsA total of 1 113 575 prescriptions were extracted, involving 38 hepatoprotective drugs such as compound glycyrrhizin, polyene phosphatidylcholine, and bicyclol. Hepatoprotective drugs were mainly in tertiary hospitals, and the highest number of prescriptions containing hepatoprotective drugs were observed in department of infectious diseases, department of gastroenterology, and department of tuberculosis. Anti-inflammatory hepatoprotective drugs accounted for the highest proportion of all prescriptions, mainly compound glycyrrhizin, polyene phosphatidylcholine, and bicyclol. Of all prescriptions, 253 429 (22.76%) had the combination of multiple hepatoprotective drugs, with the highest number of 6 drugs, among which polyene phosphatidylcholine combined with bicyclol accounted for the highest proportion. ConclusionThere are large quantities of hepatoprotective drugs used by outpatients in China. At present, the hepatoprotective drugs are clinically applied rationally, but there are still some problems to be solved, such as the combination of drugs.ZHAO ZinanEditorial Department of Journal of Clinical HepatologyarticleDiseases of the digestive system. GastroenterologyRC799-869ZHLinchuang Gandanbing Zazhi, Vol 37, Iss 11, Pp 2595-2599 (2021)
institution	DOAJ
collection	DOAJ
language	ZH
topic	Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	Diseases of the digestive system. Gastroenterology RC799-869 ZHAO Zinan A real-world data analysis of the use of hepatoprotective drugs in outpatients in six cities of China from 2015 to 2019
description	ObjectiveTo investigate the use of hepatoprotective drugs in China in recent years, and to put forward related suggestions. MethodsThe outpatient prescription data of hepatoprotective drugs were collected from 85 hospitals in 6 cities of China from 2015 to 2019, and a real-world data analysis was performed to analyze the payment method, issuing department, drug category, and use of hepatoprotective drugs. ResultsA total of 1 113 575 prescriptions were extracted, involving 38 hepatoprotective drugs such as compound glycyrrhizin, polyene phosphatidylcholine, and bicyclol. Hepatoprotective drugs were mainly in tertiary hospitals, and the highest number of prescriptions containing hepatoprotective drugs were observed in department of infectious diseases, department of gastroenterology, and department of tuberculosis. Anti-inflammatory hepatoprotective drugs accounted for the highest proportion of all prescriptions, mainly compound glycyrrhizin, polyene phosphatidylcholine, and bicyclol. Of all prescriptions, 253 429 (22.76%) had the combination of multiple hepatoprotective drugs, with the highest number of 6 drugs, among which polyene phosphatidylcholine combined with bicyclol accounted for the highest proportion. ConclusionThere are large quantities of hepatoprotective drugs used by outpatients in China. At present, the hepatoprotective drugs are clinically applied rationally, but there are still some problems to be solved, such as the combination of drugs.
format	article
author	ZHAO Zinan
author_facet	ZHAO Zinan
author_sort	ZHAO Zinan
title	A real-world data analysis of the use of hepatoprotective drugs in outpatients in six cities of China from 2015 to 2019
title_short	A real-world data analysis of the use of hepatoprotective drugs in outpatients in six cities of China from 2015 to 2019
title_full	A real-world data analysis of the use of hepatoprotective drugs in outpatients in six cities of China from 2015 to 2019
title_fullStr	A real-world data analysis of the use of hepatoprotective drugs in outpatients in six cities of China from 2015 to 2019
title_full_unstemmed	A real-world data analysis of the use of hepatoprotective drugs in outpatients in six cities of China from 2015 to 2019
title_sort	real-world data analysis of the use of hepatoprotective drugs in outpatients in six cities of china from 2015 to 2019
publisher	Editorial Department of Journal of Clinical Hepatology
publishDate	2021
url	https://doaj.org/article/fb411e4816824d9692d1b197993f36d8
work_keys_str_mv	AT zhaozinan arealworlddataanalysisoftheuseofhepatoprotectivedrugsinoutpatientsinsixcitiesofchinafrom2015to2019 AT zhaozinan realworlddataanalysisoftheuseofhepatoprotectivedrugsinoutpatientsinsixcitiesofchinafrom2015to2019
_version_	1718425647601156096

A real-world data analysis of the use of hepatoprotective drugs in outpatients in six cities of China from 2015 to 2019

Ejemplares similares